Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain (PARA_OA_002)

Paradigm Biopharmaceuticals · ClinicalTrials.gov registration

Phase 2/3 adaptive trial (primary endpoint WOMAC pain at day 56); listed active-not-recruiting with no peer-reviewed symptom results published as of August 2026.

Population

Adults with knee osteoarthritis pain (multinational, two-stage adaptive design)

Intervention

Subcutaneous injectable PPS, multiple dosing regimens

Comparator

Placebo

Limitations

Registration record only — included for tracking; company press releases are not peer-reviewed results.